‘We Are Going To See A Season’: Reckitt Flags Uptick In Cold & Flu
Early sell-out data lifts Reckitt’s winter outlook, while Durex returns to growth. A China VMS slowdown and a Lysol supply issue drive a cut to 2026 revenue guidance.
HBW Insight - October 29, 2026

As North America Sales Grow In Q3, Sandoz Prepares For US Eylea Rival Launch
Sandoz's Q3 2026 biosimilars revenues grew 17%, driven by North America, while European growth was dented by unexpected demand surge in Germany. Presenting the results, CEO Richard Saynor also pushed for antibiotic dumping protection in Europe.
Generics Bulletin - October 29, 2026

Ferring Doubles Down In Fertility With Up To $1.38bn Gameto Buy
Deal Snapshot: The private Swiss company is acquiring the Texas-based biotech and its Phase III asset that aims to make IVF and egg freezing shorter and less reliant on hormone injections.
Scrip - October 29, 2026

Lilly And Merck Look To Compete In First-Line KRAS G12C Lung Cancer
Eli Lilly will be first with Phase III data in frontline in KRAS G12C lung cancer treatment but Merck and Roche will be close behind with competitive assets.
Scrip - October 29, 2026

J&J Vision’s New Chief Pitches Lifetime Eye Care As Alcon And Rivals Press Its Surgical Arm
Jacqueline Henderson, J&J’s permanent Vision chief, pitches lifetime eye care across contact lenses and IOLs, while Alcon and new entrants press J&J’s surgical business and its newest reusable lens lacks US approval.
Medtech Insight - October 29, 2026

DermaSensor Skin Lesion Assessment Tool, Samsung Sleep Apnea Feature Among New FDA Classifications
Four device types that reached market through the De Novo pathway have been granted Class II status under a set of FDA orders set for publication on Oct. 30.
Medtech Insight - October 29, 2026

New FDA Guidance Would Make eSTAR Mandatory For Investigational Device Exemptions
US regulator continues its push to improve submission acceptance rates via electronic template system.
Medtech Insight - October 29, 2026

Boston Scientific’s Cyberattack Cuts Guidance And Warns Of 2027 ‘Trough’ As FARAWAVE Ultra, FARAFLEX
A cyberattack cost Boston Scientific about 300 bps of Q3 growth and will weigh on Q4, but delayed FARAWAVE Ultra and FARAFLEX launches leave electrophysiology ceding share through 2027, which management now calls the trough.
Medtech Insight - October 29, 2026

Adalvo Takes On Amgen’s Nplate With Enzene Biosimilar Purchase
Adalvo has acquired a biosimilar program from Enzene, strengthening its biosimilar portfolio and aligning with the company's wider targets to expand development into complex biological medicines.
Generics Bulletin - October 29, 2026

Canada’s Biosimilar Switching Schemes: An Uptake Model For Others To Emulate?
Canada’s provincial biosimilar switching programs have been successful and may provide a model for others to follow, but could be further improved with shorter transition periods, Biosimilars Canada’s Jody Cox told an IGBA webinar.
Generics Bulletin - October 29, 2026

EU Council Plans Stronger Trade Secret Protections For Medtech Under Data Act
Pushback from Germany and France has secured a key win for medtech in Data Act amendment negotiations, but the industry still faces regulatory overlap with MDR and IVDR.
Medtech Insight - October 29, 2026

Lilly’s Retatrutide Tops Ozempic In Head-To-Head Trial, With A Tolerability Tradeoff
Lilly's latest retatrutide data put the spotlight on its next test: a head-to-head trial against its own tirzepatide.
Scrip - October 29, 2026

Biopharma’s Data Imperative: Driving Precision and Patient Impact
Much of oncology’s most useful real-world evidence sits in free-text clinical notes. Validated AI and natural language processing can make it research-ready, but only if biopharma shifts its focus from cohort size to data depth, quality and trust.
In Vivo - October 29, 2026

Bausch + Lomb Sees Lumify Line Extension Approval And Launch In Growing Confidence
B+L reports Lumify OTC eye drop sales growing 38% were a key revenue driver for its 7% overall Q3 growth to $1.38bn in the first results announced with Thomas Appio as interim CEO two weeks after Brent Saunders’ exit from the post.
HBW Insight - October 29, 2026

US Sunscreens With BEMT Lose PETA Cruelty-Free Status, Says NGO
PETA is warning sunscreen brands that using FDA-approved bemotrizinol could cost them their place on the organization’s Ultimate Cruelty-Free List.
HBW Insight - October 29, 2026